drugset / Trial / NCT02340572
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080
Phase 1
Completed
48 enrolled
Pieris Pharmaceuticals GmbH
EUROCALIN Consortium · collabFGK Clinical Research GmbH · collabNuvisan Pharma Services · collab
RandomizedParallel-groupDouble-blind
Summary
Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for treatment of anemia of chronic disease. This phase I First-in-Human study shall investigate safety and pharmacokinetics in healthy human volunteers.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-07
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRS-080#022-DP | Unknown | — | Intravenous |
Indications
No indication recorded.